APOE and Alzheimer disease: In addition to AD risk, APOE ε4 carriers, especially those who are APOE ε4/ε4 homozygotes, exhibit an increased susceptibility to Amyloid-Related Imaging Abnormalities (ARIA) when treated with anti-amyloid antibodies [10, 11].